Healthcare
ProKidney Corp.(PROK)
Live Price
Offline$1.83
+4.57% today
1Y Change
+201.98%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $560.00M
- Revenue Growth
- +1075.0%
- EPS Growth
- +16.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProKidney Corp. (PROK) is a Healthcare stock with a market cap of $560.00M and listed on NASDAQ. The stock last traded around $1.83 and up 202.0% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +1075.0%, EPS growth of +16.1%, a dividend yield of 0.0%. What stands out right now is revenue +1075.0%, EPS +16.1%, free cash flow +13.2% with operating margin -18477.8% and ROIC -54.1%. Valuation already assumes a fairly strong business story at price/sales 625.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PROK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1075.0% vs +7.6% peer median
Operating Margin
Below sector median
-18477.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1075.0% and EPS at +16.1%, with operating margin around -18477.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +0.6% | -9.0% | -5.6% |
2026 Mar 18, 2026 | +12.5% | -6.3% | -12.0% | -6.3% |
2025 Nov 10, 2025 | +0.0% | +3.7% | -16.7% | -18.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PROK Max Drawdown
-70.08%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PROK and SPY.
Company Overview
ProKidney Corp.
NASDAQ Capital Market
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
- Leadership
- Bruce Culleton
- IPO Date
- Jun 30, 2021
- Employees
- 204
- Street Address
- 2000 Frontis Plaza Blvd.
- Mailing
- Winston-Salem, NC, 27103
- Region
- Winston-Salem, NC, US
- Reporting Currency
- USD
- Investor Line
- 336 999 7028
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 625.7
- Price/Book
- โ
Growth
- Revenue
- +1075.0%
- EPS
- +16.1%
- Free Cash Flow
- +13.2%
Profitability
- Gross Margin
- -218.8%
- Operating Margin
- -18477.8%
- Net Margin
- -7725.2%
- ROE
- 6.9%
- ROIC
- -54.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 9.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.